我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
95
44 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
35
36.8%
尚未招募
44
46.3%
招募中
16
16.8%
暂无批准数据
- Fosnetupitant achieved a significantly higher no-vomiting rate (100%) versus fosaprepitant (91.2%) during the long-delayed phase (days 6–7) in a propensity score-matched analysis (p=0.028). - Over the entire 7-day period, the no-vomiting rate was 95.6% with fosnetupitant compared to 83.8% with fosaprepitant (p=0.045), with a hazard ratio of 0.20 for vomiting events. - Injection site reactions were significantly less frequent with fosnetupitant (0.0%) than with fosaprepitant (19.1%, p<0.001), suggesting a more favorable safety profile. - The findings support fosnetupitant as a promising NK1 receptor antagonist for antiemetic prophylaxis in oxaliplatin-irinotecan combination regimens where guideline recommendations remain inconsistent.
